Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review)

Lin,Li; Xiang,Shaowei; Chen,Yuan; Liu,Yan; Shen,Dingwen; Yu,Xiaoping; Wu,Zhe; Sun,Yanling; Chen,Kequan; Luo,Jia; Wei,Guilai; Wang,Zhiguo; Ning,Zhifeng

doi:10.3892/etm.2024.12716

Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review)

Authors:
- Li Lin
- Shaowei Xiang
- Yuan Chen
- Yan Liu
- Dingwen Shen
- Xiaoping Yu
- Zhe Wu
- Yanling Sun
- Kequan Chen
- Jia Luo
- Guilai Wei
- Zhiguo Wang
- Zhifeng Ning
View Affiliations

Affiliations: Department of Biochemistry, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Neurosurgery, Enshi State Central Hospital, Enshi, Hubei 445000, P.R. China, Department of Cardiothoracic Surgery, The First Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Internal Medicine, The Second Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Parasitology, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Function, The Second Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Histology and Embryology, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Cardiovascular Medicine, The Second Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, School of Sport, Xianning Vocational and Technical College, Xianning, Hubei 437100, P.R. China, School of Art and Design, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Dermatology, The First Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Human Anatomy, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China
Published online on: September 11, 2024 https://doi.org/10.3892/etm.2024.12716
Article Number: 427
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gut microbiota refers to the diverse bacterial community residing in the gastrointestinal tract. Recent data indicate a strong correlation between alterations in the gut microbiota composition and the onset of various diseases, notably cardiovascular disorders. Evidence suggests the gut‑cardiovascular axis signaling molecules released by the gut microbiota play a pivotal role in regulation. This review systematically delineates the association between dysbiosis of the gut microbiota and prevalent cardiovascular diseases, including atherosclerosis, hypertension, myocardial infarction and heart failure. Furthermore, it provides an overview of the putative pathogenic mechanisms by which dysbiosis in the gut microbiota contributes to the progression of cardiovascular ailments. The potential modulation of gut microbiota as a preventive strategy against cardiovascular diseases through dietary interventions, antibiotic therapies and probiotic supplementation is also explored and discussed within the present study.

View Figures

View References

1	Barreto HC and Gordo I: Intrahost evolution of the gut microbiota. Nat Rev Microbiol. 21:590–603. 2023.PubMed/NCBI View Article : Google Scholar
2	Guarner F and Malagelada JR: Gut flora in health and disease. Lancet. 361:512–519. 2003.PubMed/NCBI View Article : Google Scholar
3	Shayya NW, Foote MS, Langfeld LQ, Du K, Bandick R, Mousani S, Bereswill S and Heimesaat MM: Human microbiota associated IL-10-/- mice: A valuable enterocolitis model to dissect the interactions of Campylobacter jejuni with host immunity and gut microbiota. Eur J Microbiol Immunol (Bp). 12:107–122. 2023.PubMed/NCBI View Article : Google Scholar
4	Couvillion SP, Danczak RE, Cao X, Yang Q, Keerthising TP, McClure RS, Bitounis D, Bunret MC, Fansler SJ, Richardson RE, et al: Graphene oxide exposure alters gut microbial community composition and metabolism in an in vitro human model. NanoImpact. 30(100463)2023.PubMed/NCBI View Article : Google Scholar
5	Mishra SP, Wang B, Jain S, Ding J, Rejeski J, Furdui CM, Kitzman DW, Taraohder S, Brechot C, Kumar A and Yadav H: A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut. Gut. 72:1848–1865. 2023.PubMed/NCBI View Article : Google Scholar
6	Vallino L, Garavaglia B, Visciglia A, Amoruso A, Pane M, Ferraresi A and Lsidoro C: Cell-free Lactiplantibacillus plantarum OC01 supernatant suppresses IL-6-induced proliferation and invasion of human colorectal cancer cells: Effect on β-Catenin degradation and induction of autophagy. J Tradit Complement Med. 13:193–206. 2023.PubMed/NCBI View Article : Google Scholar
7	Hooper LV and Gordon JI: Commensal host-bacterial relationships in the gut. Science. 292:1115–1118. 2001.PubMed/NCBI View Article : Google Scholar
8	Dethlefsen L, McFall-Ngai M and Relman DA: An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature. 449:811–818. 2007.PubMed/NCBI View Article : Google Scholar
9	Maciel-Fiuza MF, Muller GC, Campos DMS, Costa PSS, Peruzzo J, Bonamigo RR, Veit T and Vianna FSL: Role of gut microbiota in infectious and inflammatory diseases. Front Microbiol. 14(1098386)2023.PubMed/NCBI View Article : Google Scholar
10	Zhao J, Hu Y, Qian C, Hussain M, Liu S, Zhang A, He R and Sun P: The interaction between mushroom polysaccharides and gut microbiota and their effect on human health: A review. Biology (Basel). 12(122)2023.PubMed/NCBI View Article : Google Scholar
11	Belvoncikova P, Splichalova P, Videnska P and Gardlik R: The human mycobiome: Colonization, composition and the role in health and disease. J Fungi. 8(1046)2022.PubMed/NCBI View Article : Google Scholar
12	Ley RE, Lozupone CA, Hamady M, Knight R and Gordon JI: Worlds within worlds: Evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 6:776–788. 2008.PubMed/NCBI View Article : Google Scholar
13	Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J and Huttenhower C: Microbial co-occurrence relationships in the human microbiome. PLoS Comput Biol. 8(e1002606)2012.PubMed/NCBI View Article : Google Scholar
14	Kwa WT, Sundarajoo S, Toh KY and Lee J: Application of emerging technologies for gut microbiome research. Singapore Med J. 64:45–52. 2023.PubMed/NCBI View Article : Google Scholar
15	Sauceda C, Bayne C, Sudqi K, Gonzalez A, Dulai PS, Knight R, Gonzalez DJ and Gonzalez C: Stool multi-omics for the study of host-microbe interactions in inflammatory bowel disease. Gut Microbes. 14(2154092)2022.PubMed/NCBI View Article : Google Scholar
16	Minj J, Riordan J, Teets C, Fernholz-Hartman H, Tanggono A, Lee Y, Chauvin T, Carbonero F and Solverson P: Diet-induced rodent obesity is prevented and the fecal microbiome is improved with elderberry (Sambucus nigra ssp. canadensis) juice powder. J Agric Food Chem. 72:12555–12565. 2024.PubMed/NCBI View Article : Google Scholar
17	Rochoń J, Kalinowski P, Szymanek-Majchrzak K and Grąt M: Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 30:2964–2980. 2024.PubMed/NCBI View Article : Google Scholar
18	Zhang Y, Zheng T, Ma D, Shi P, Zhang H, Li J and Sun Z: Probiotics Bifidobacterium lactis M8 and Lactobacillus rhamnosus M9 prevent high blood pressure via modulating the gut microbiota composition and host metabolic products. mSystems. 8(e0033123)2023.PubMed/NCBI View Article : Google Scholar
19	Yan D, Si W, Zhou X, Yang M, Chen Y, Chang Y, Lu Y, Liu J, Wang K, Yan M, et al: Eucommia ulmoides bark extract reduces blood pressure and inflammation by regulating the gut microbiota and enriching the Parabacteroides strain in high-salt diet and N(omega)-nitro-L-arginine methyl ester induced mice. Front Microbiol. 18(967649)2022.PubMed/NCBI View Article : Google Scholar
20	Mao Y, Kong C, Zang T, You L, Wang LS, Shen L and Ge JB: Impact of the gut microbiome on atherosclerosis. mLife. 3:167–175. 2024.PubMed/NCBI View Article : Google Scholar
21	Glorieux G, Nigam SK, Vanholder R and Verbeke F: Role of the microbiome in gut-heart-kidney cross talk. Circ Res. 132:1064–1083. 2023.PubMed/NCBI View Article : Google Scholar
22	Hijová E: Benefits of biotics for cardiovascular diseases. Int J Mol Sci. 24(6292)2023.PubMed/NCBI View Article : Google Scholar
23	Liao L, Huang J, Zheng J, Ma X, Huang L and Xu W: Gut microbiota in Chinese and Japanese patients with cardiovascular diseases: A systematic review and meta-analysis. Ann Saudi Med. 43:105–114. 2023.PubMed/NCBI View Article : Google Scholar
24	Zhang H, Li H, Pan B, Zhang S, Su X, Sun W, Zhang T, Zhang Z, Lv S and Cui H: Integrated 16S rRNA Sequencing and untargeted metabolomics analysis to reveal the protective mechanisms of polygonatum sibiricum polysaccharide on type 2 diabetes mellitus model rats. Curr Drug Metab. 10(1389200224666230406114012)2023.PubMed/NCBI View Article : Google Scholar
25	Song Z, Song R, Liu Y, Wu Z and Zhang X: Effects of ultra-processed foods on the microbiota-gut-brain axis: The bread-and-butter issue. Food Res Int. 167(112730)2023.PubMed/NCBI View Article : Google Scholar
26	Sajdel-Sulkowska EM: Neuropsychiatric ramifications of COVID-19: Short-chain fatty acid deficiency and disturbance of microbiota-gut-brain axis signaling. Biomed Res Int. 2021(7880448)2021.PubMed/NCBI View Article : Google Scholar
27	Shantsila E, Kamphuisen PW and Lip GY: Circulating microparticles in cardiovascular disease: Implications for atherogenesis and atherothrombosis. J Thromb Haemost. 8:2358–2368. 2010.PubMed/NCBI View Article : Google Scholar
28	Philippova M, Suter Y, Toggweiler S, Schoenenberger AW, Joshi MB, Kyriakakis E, Erne P and Resink TJ: T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis. Eur Heart J. 32:760–771. 2011.PubMed/NCBI View Article : Google Scholar
29	Markin AM, Markina YV, Bogatyreva AI, Tolstik TV, Chakal DA, Breshenkov DG and Charchyan ER: The role of cytokines in cholesterol accumulation in cells and atherosclerosis progression. Int J Mol Sci. 24(6426)2023.PubMed/NCBI View Article : Google Scholar
30	Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F and Nielsen J: Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 3(1245)2012.PubMed/NCBI View Article : Google Scholar
31	Khalili L, Centner AM and Salazar G: Effects of berries, phytochemicals, and probiotics on atherosclerosis through gut microbiota modification: A meta-analysis of animal studies. Int J Mol Sci. 24(3084)2023.PubMed/NCBI View Article : Google Scholar
32	Kumar T, Dutta RR, Velagala VR, Ghosh B and Mudey A: Analyzing the complicated connection between intestinal microbiota and cardiovascular diseases. Cureus. 14(e28165)2022.PubMed/NCBI View Article : Google Scholar
33	Shi X, Wu H, Liu Y, Huang H, Liu L, Yang Y, Jiang T, Zhou M and Dai M: Inhibiting vascular smooth muscle cell proliferation mediated by osteopontin via regulating gut microbial lipopolysaccharide: A novel mechanism for paeonol in atherosclerosis treatment. Front Pharmacol. 13(936677)2022.PubMed/NCBI View Article : Google Scholar
34	Liu S, He F, Zheng T, Wan S, Chen S, Yang F, Xu X and Pei X: Ligustrum robustum alleviates atherosclerosis by decreasing serum TMAO, modulating gut microbiota, and decreasing bile acid and cholesterol absorption in mice. Mol Nutr Food Res. 65(e2100014)2021.PubMed/NCBI View Article : Google Scholar
35	Zhen J, Zhou Z, He M, Han HX, Lv EH, Wen PB, Liu X, Wang YT, Cai XC, Tian JQ, et al: The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 14(1085041)2023.PubMed/NCBI View Article : Google Scholar
36	Canyelles M, Tondo M, Cedó L, Farràs M, Escolà-Gil JC and Blanco-Vaca F: Trimethylamine N-Oxide: A link among diet, gut microbiota, gene regulation of liver and intestine cholesterol homeostasis and HDL function. Int J Mol Sci. 19(3228)2018.PubMed/NCBI View Article : Google Scholar
37	Shi C, Pei M, Wang Y, Chen Q, Cao P, Zhang L, Guo J, Deng W, Wang L, Li X and Gong Z: Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. Biochem Biophys Res Commun. 594:1–7. 2022.PubMed/NCBI View Article : Google Scholar
38	Trenteseaux C, Gaston AT, Aguesse A, Poupeau G, Coppet P, Andriantsitohaina R, Laschet J, Amarger V, Krempf M, Nobecourt-Dupuy E and Ouguerram K: Perinatal hypercholesterolemia exacerbates atherosclerosis lesions in offspring by altering metabolism of trimethylamine-n-oxide and bile acids. Arterioscler Thromb Vasc Biol. 37:2053–2063. 2017.PubMed/NCBI View Article : Google Scholar
39	Schleifer KH and Kandler O: Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev. 36:407–477. 1972.PubMed/NCBI View Article : Google Scholar
40	Popescu NI, Girton A, Burgett T, Lovelady K and Coggeshall KM: Monocyte procoagulant responses to anthrax peptidoglycan are reinforced by proinflammatory cytokine signaling. Blood Adv. 3:2436–2447. 2019.PubMed/NCBI View Article : Google Scholar
41	Xie Y, Li Y, Cai X, Wang X and Li J: Interleukin-37 suppresses ICAM-1 expression in parallel with NF-κB down-regulation following TLR2 activation of human coronary artery endothelial cells. Int Immunopharmacol. 38:26–30. 2016.PubMed/NCBI View Article : Google Scholar
42	Dong C, Zhang M, Song S, Wei F, Qin L, Fan P, Shi Y, Wang X and Wang R: A small subunit of Geranylgeranyl Diphosphate synthase functions as an active regulator of carotenoid synthesis in nicotiana tabacum. Int J Mol Sci. 24(992)2023.PubMed/NCBI View Article : Google Scholar
43	Jo HE, Son SY and Lee CH: Comparison of metabolome and functional properties of three Korean cucumber cultivars. Front Plant Sci. 13(882120)2022.PubMed/NCBI View Article : Google Scholar
44	Bocchini M, D'Amato R, Ciancaleoni S, Fontanella MC, Palmerini CA, Beone GM, Onofri A, Negri V, Marconi G, Albertini E and Businelli D: Soil Selenium (Se) biofortification changes the physiological, biochemical and epigenetic responses to water stress in Zea mays L. by inducing a higher drought tolerance. Front Plant Sci. 9(389)2018.PubMed/NCBI View Article : Google Scholar
45	Wang Y, Zheng Y, Liu Y, Shan G, Zhang B, Cai Q, Lou J and Qu Y: The lipid-lowering effects of fenugreek gum, hawthorn pectin, and burdock inulin. Front Nutr. 10(1149094)2023.PubMed/NCBI View Article : Google Scholar
46	Tahri K, Grill JP and Schneider F: Bifidobacteria strain behavior toward cholesterol: Coprecipitation with bile salts and assimilation. Curr Microbiol. 33:187–193. 1996.PubMed/NCBI View Article : Google Scholar
47	Bordoni A, Amaretti A, Leonardi A, Boschetti E, Danesi F, Matteuzzi D, Roncaglia L, Raimondi S and Rossi M: Cholesterol-lowering probiotics: In vitro selection and in vivo testing of bifidobacteria. Appl Microbiol Biotechnol. 97:8273–8281. 2013.PubMed/NCBI View Article : Google Scholar
48	Burnier M and Damianaki A: Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res. 132:1050–1063. 2023.PubMed/NCBI View Article : Google Scholar
49	Mutengo KH, Masenga SK, Mweemba A, Mutale W and Kirabo A: Gut microbiota dependant trimethylamine N-oxide and hypertension. Front Physiol. 14(1075641)2023.PubMed/NCBI View Article : Google Scholar
50	Honour JW, Borriello SP, Ganten U and Honour P: Antibiotics attenuate experimental hypertension in rats. J Endocrinol. 105:347–350. 1985.PubMed/NCBI View Article : Google Scholar
51	Yang Z, Wang Q, Liu Y, Wang L, Ge Z, Li Z, Feng S and Wu C: Gut microbiota and hypertension: Association, mechanisms and treatment. Clin Exp Hypertens. 45(2195135)2023.PubMed/NCBI View Article : Google Scholar
52	Li J, Zhao F, Wang Y, Chen J, Tao G, Tian G, Wu S, Liu W, Cui Q, Geng B, et al: Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 5(14)2017.PubMed/NCBI View Article : Google Scholar
53	Jin J, Gao L, Zou X, Zhang Y, Zheng Z, Zhang X, Li J, Tian Z, Wang X, Gu J, et al: Gut dysbiosis promotes preeclampsia by regulating macrophages and trophoblasts. Circ Res. 131:492–506. 2022.PubMed/NCBI View Article : Google Scholar
54	Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M and Nitert MD: SPRING Trial Group. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension. 68:974–981. 2016.PubMed/NCBI View Article : Google Scholar
55	Lucas SE, Walton SL, Colafella KM, Mileto SJ, Lyras D and Denton KM: Antihypertensives and antibiotics: Impact on intestinal dysfunction and hypertension. Hypertension. 11:1393–1402. 2023.PubMed/NCBI View Article : Google Scholar
56	Kyoung J and Yang T: Depletion of the gut microbiota enhances the blood pressure-lowering effect of captopril: Implication of the gut microbiota in resistant hypertension. Hypertens Res. 45:1505–1510. 2022.PubMed/NCBI View Article : Google Scholar
57	Chen XF, Ren SC, Tang G, Wu C, Chen X and Tang XQ: Short-chain fatty acids in blood pressure, friend or foe. Chin Med J (Engl). 134:2393–2394. 2021.PubMed/NCBI View Article : Google Scholar
58	Dinakis E, O'Donnell JA and Marques FZ: The gut-immune axis during hypertension and cardiovascular diseases. Acta Physiol (Oxf). 20(e14193)2024.PubMed/NCBI View Article : Google Scholar
59	Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, He L, et al: Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na⁺ uptake in humans. Sci Transl Med. 6(277ra36)2014.PubMed/NCBI View Article : Google Scholar
60	Ohman KP, Karlberg BE, Nilsson OR and Wettre S: Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems. Acta Med Scand Suppl. 646:98–105. 1981.PubMed/NCBI
61	Andrade JM, de Farias Lelis D, Mafra V and Cota J: The angiotensin converting enzyme 2 (ACE2), gut microbiota, and cardiovascular health. Protein Pept Lett. 24:827–832. 2017.PubMed/NCBI View Article : Google Scholar
62	Perlot T and Penninger JM: ACE2-from the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect. 15:866–873. 2013.PubMed/NCBI View Article : Google Scholar
63	Zhang QL, Chen XH, Zhou SJ, Lei YQ, Huang JS, Chen Q and Cao H: Relationship between disorders of the intestinal microbiota and heart failure in infants with congenital heart disease. Front Cell Infect Microbiol. 13(1152348)2023.PubMed/NCBI View Article : Google Scholar
64	Desai D, Desai A, Jamil A, Csendes D, Gutlapalli SD, Prakash K, Swarnakari KM, Bai M, Manoharan MP, Raja R and Khan S: Re-defining the gut heart axis: A systematic review of the literature on the role of gut microbial dysbiosis in patients with heart failure. Cureus. 15(e34902)2023.PubMed/NCBI View Article : Google Scholar
65	Xu X, Hu H, Zeng H, Li B, Yin Q, Jiang Y, Zang L, Zhao C and Qian G: Sinisan ameliorates colonic injury induced by water immersion restraint stress by enhancing intestinal barrier function and the gut microbiota structure. Pharm Biol. 61:598–609. 2023.PubMed/NCBI View Article : Google Scholar
66	Tousoulis D, Guzik T, Padro T, Duncker DJ, Luca GD, Eringa E, Vavlukis M, Antonopoulos AS, Katsimichas T, Cenko E, et al: Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: A position paper by the ESC working group on coronary pathophysiology and microcirculation. Cardiovasc Res. 118:3171–3182. 2022.PubMed/NCBI View Article : Google Scholar
67	Cui X, Su Y, Huang X, Chen J, Ma J, Liao P and He X: Combined analysis of plasma metabolome and intestinal microbiome sequencing to explore jiashen prescription and its potential role in changing intestine-heart axis and effect on chronic heart failure. Front Cardiovasc Med. 10(1147438)2023.PubMed/NCBI View Article : Google Scholar
68	Zong X, Fan Q, Yang Q, Pan R, Zhuang L, Xi R, Zhang R and Tao R: Trimethyllysine, a trimethylamine N-oxide precursor, predicts the presence, severity, and prognosis of heart failure. Front Cardiovasc Med. 9(907997)2022.PubMed/NCBI View Article : Google Scholar
69	Li X, Fan Z, Cui J, Li D, Lu J, Cui X, Xie L, Wu Y, Lin Q and Li Y: Trimethylamine N-Oxide in heart failure: A meta-analysis of prognostic value. Front Cardiovasc Med. 16(817396)2022.PubMed/NCBI View Article : Google Scholar
70	Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y and Hazen SL: Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 35:904–910. 2014.PubMed/NCBI View Article : Google Scholar
71	Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein EB, Britt EB, Fu X, Chung YM, et al: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 472:57–63. 2011.PubMed/NCBI View Article : Google Scholar
72	Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzmman NH and Baker JE: Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 26:1727–1735. 2012.PubMed/NCBI View Article : Google Scholar
73	Lam V, Su J, Hsu A, Gross GJ, Salzman NH and Baker JE: Intestinal microbial metabolites are linked to severity of myocardial infarction in rats. PLoS One. 11(e0160840)2016.PubMed/NCBI View Article : Google Scholar
74	Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, Sidaway JE, Martin G, Gloor GB, Swann JR, et al: Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail. 7:491–499. 2014.PubMed/NCBI View Article : Google Scholar
75	Tang WH and Hazen SL: The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 124:4204–4211. 2014.PubMed/NCBI View Article : Google Scholar
76	Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF and Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 101:15718–15723. 2004.PubMed/NCBI View Article : Google Scholar
77	Jones BV, Begley M, Hill C, Gahan CG and Marchesi JR: Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA. 105:13580–13585. 2008.PubMed/NCBI View Article : Google Scholar
78	Chiang JY: Bile acids: Regulation of synthesis. J Lipid Res. 50:1955–1966. 2009.PubMed/NCBI View Article : Google Scholar
79	Ferrell JM, Boehme S, Li F and Chiang JY: Cholesterol 7α-hydroxylase-deficient mice are protected from high-fat/high-cholesterol diet-induced metabolic disorders. J Lipid Res. 57:1144–1154. 2016.PubMed/NCBI View Article : Google Scholar
80	Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, Erickson SK and Chiang JY: Glucose and insulin induction of bile acid synthesis: Mechanisms and implication in diabetes and obesity. J Biol Chem. 287:1861–1873. 2012.PubMed/NCBI View Article : Google Scholar
81	Broeders EP, Nascimento EB, Havekes B, Brans B, Roumans KH, Tailleux A, Schaart G, Kouach M, Charton J, Deprez B, et al: The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab. 22:418–426. 2015.PubMed/NCBI View Article : Google Scholar
82	Kumar PS, Mason MR, Brooker MR and O'Brien K: Pyrosequencing reveals unique microbial signatures associated with healthy and failing dental implants. J Clin Periodontol. 39:425–433. 2012.PubMed/NCBI View Article : Google Scholar
83	Mayerhofer CCK, Ueland T, Broch K, Vincent RP, Cross GF, Dahl CP, Aukrust P, Gullestad L, Hov JR and Trøseid M: Increased Secondary/Primary bile acid ratio in chronic heart failure. J Card Fail. 23:666–671. 2017.PubMed/NCBI View Article : Google Scholar
84	Dam H: The formation of coprosterol in the intestine: The action of intestinal bacteria on cholesterol. Biochem J. 28:820–825. 1934.PubMed/NCBI View Article : Google Scholar
85	Lichtenstein AH: Intestinal cholesterol metabolism. Ann Med. 22:49–52. 1990.PubMed/NCBI View Article : Google Scholar
86	Illman RJ, Storer GB and Topping DL: White wheat flour lowers plasma cholesterol and increases cecal steroids relative to whole wheat flour, wheat bran and wheat pollard in rats. J Nutr. 123:1094–1100. 1993.PubMed/NCBI View Article : Google Scholar
87	Midtvedt AC and Midtvedt T: Conversion of cholesterol to coprostanol by the intestinal microflora during the first two years of human life. J Pediatr Gastroenterol Nutr. 17:161–168. 1993.PubMed/NCBI View Article : Google Scholar
88	Benno P, Midtvedt K, Alam M, Collinder E, Norin E and Midtvedt T: Examination of intestinal conversion of cholesterol to coprostanol in 633 healthy subjects reveals an age- and sex-dependent pattern. Microbial Ecology in Health and Disease. 17:200–204. 2005.
89	Midtvedt T, Lingaas E, Carlstedt-Duke B, Höverstad T, Midtvedt AC, Saxerholt H, Steinbakk M and Norin KE: Intestinal microbial conversion of cholesterol to coprostanol in man. Influence of antibiotics. APMIS. 98:839–844. 1990.PubMed/NCBI View Article : Google Scholar
90	Veiga P, Juste C, Lepercq P, Saunier K, Béguet F and Gérard P: Correlation between faecal microbial community structure and cholesterol-to-coprostanol conversion in the human gut. FEMS Microbiol Lett. 242:81–86. 2005.PubMed/NCBI View Article : Google Scholar
91	Gerard P, Lepercq P, Leclerc M, Gavini F, Raibaud P and Juste C: Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces. Appl Environ Microbiol. 73:5742–5749. 2007.PubMed/NCBI View Article : Google Scholar
92	Ren D, Li L, Schwabacher AW, Young JW and Beitz DC: Mechanism of cholesterol reduction to coprostanol by Eubacterium coprostanoligenes ATCC 51222. Steroids. 61:33–40. 1996.PubMed/NCBI View Article : Google Scholar
93	Li L, Baumann CA, Meling DD, Sell JL and Beitz DC: Effect of orally administered Eubacterium Coprostanoligenes ATCC 51222 on plasma cholesterol concentration in laying hens. Poult Sci. 75:743–745. 1996.PubMed/NCBI View Article : Google Scholar
94	Rosenfeld RS, Fukushima DK, Hellman L and Gallagher TF: The transformation of cholesterol to coprostanol. J Biol Chem. 211:301–311. 1954.PubMed/NCBI
95	Antharam VC, McEwen DC, Garrett TJ, Dossey AT, Li EC, Kozlov AN, Mesbah Z and Wang GP: An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in clostridium difficile infection. PLoS One. 11(e0148824)2016.PubMed/NCBI View Article : Google Scholar
96	Lye HS, Rusul G and Liong MT: Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. J Dairy Sci. 93:1383–1392. 2010.PubMed/NCBI View Article : Google Scholar
97	Tahri K, Grill JP and Schneider F: Involvement of trihydroxyconjugated bile salts in cholesterol assimilation by bifidobacteria. Curr Microbiol. 34:79–84. 1997.PubMed/NCBI View Article : Google Scholar
98	Gérard P: Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 3:14–24. 2013.PubMed/NCBI View Article : Google Scholar
99	Nutting CW, Islam S and Daugirdas JT: Vasorelaxant effects of short chain fatty acid salts in rat caudal artery. Am J Physiol. 261:H561–H567. 1991.PubMed/NCBI View Article : Google Scholar
100	Macfarlane GT and Macfarlane S: Fermentation in the human large intestine: Its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol. 45 (Suppl):S120–S127. 2011.PubMed/NCBI View Article : Google Scholar
101	Musso G, Gambino R and Cassader M: Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 62:361–380. 2011.PubMed/NCBI View Article : Google Scholar
102	David LA, Maurice CF, Carmody RN, Gootenbreg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al: Diet rapidly and reproducibly alters the human gut microbiome. Nature. 505:559–563. 2014.PubMed/NCBI View Article : Google Scholar
103	Krishnan S, Alden N and Lee K: Pathways and functions of gut microbiota metabolism impacting host physiology. Curr Opin Biotechnol. 36:137–145. 2015.PubMed/NCBI View Article : Google Scholar
104	Pluznick J: A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 5:202–207. 2014.PubMed/NCBI View Article : Google Scholar
105	Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, et al: Gut dysbiosis is linked to hypertension. Hypertension. 65:1331–1340. 2015.PubMed/NCBI View Article : Google Scholar
106	Jama HA, Snelson M, Schutte AE, Muir J and Marques FZ: Recommendations for the use of dietary fiber to improve blood pressure control. Hypertension. 81:1450–1459. 2024.PubMed/NCBI View Article : Google Scholar
107	Falony G, Vieira-Silva S and Raes J: Microbiology meets big data: The case of gut microbiota-derived Trimethylamine. Annu Rev Microbiol. 69:305–321. 2015.PubMed/NCBI View Article : Google Scholar
108	Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 19:576–585. 2013.PubMed/NCBI View Article : Google Scholar
109	Zeisel SH and Warrier M: Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annu Rev Nutr. 37:157–181. 2017.PubMed/NCBI View Article : Google Scholar
110	Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y and Hazen SL: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 368:1575–1584. 2013.PubMed/NCBI View Article : Google Scholar
111	Chittim CL, del Campo AM and Balskus EP: Gut bacterial phospholipase Ds support disease-associated metabolism by generating choline. Nat Microbiol. 4:155–163. 2019.PubMed/NCBI View Article : Google Scholar
112	Allayee H and Hazen SL: Contribution of gut bacteria to lipid levels: Another metabolic role for microbes? Circ Res. 117:750–754. 2015.PubMed/NCBI View Article : Google Scholar
113	Ghazalpour A, Cespedes I, Bennett BJ and Allayee H: Expanding role of gut microbiota in lipid metabolism. Curr Opin Lipidol. 27:141–147. 2016.PubMed/NCBI View Article : Google Scholar
114	Al-Obaide MAI, Singh R, Datta P, Rewers-Felkins KA, Salguero MV, Al-Obaidi I, Kottapalli KR and Vasylyeva TL: Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J Clin Med. 6(86)2017.PubMed/NCBI View Article : Google Scholar
115	Zhu W, Gregory JC, Org E, Buffa JA, Gupte N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, et al: Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 165:111–124. 2016.PubMed/NCBI View Article : Google Scholar
116	Ley RE, Turnbaugh PJ, Klein S and Gordon JI: Microbial ecology: Human gut microbes associated with obesity. Nature. 444:1022–1023. 2006.PubMed/NCBI View Article : Google Scholar
117	Liu TX, Niu HT and Zhang SY: Intestinal microbiota metabolism and atherosclerosis. Chin Med J (Engl). 128:2805–2811. 2015.PubMed/NCBI View Article : Google Scholar
118	Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Oeg E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK, et al: Non-lethal inhibition of gut microbial Trimethylamine production for the treatment of atherosclerosis. Cell. 163:1585–1595. 2015.PubMed/NCBI View Article : Google Scholar
119	Martin FP, Wang Y, Sprenger N, Yap IKS, Lundsedt T, Lek P, Rezzi S, Ramadan Z, van Bladeren P, Fay LB, et al: Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol. 4(157)2008.PubMed/NCBI View Article : Google Scholar
120	Nakamura Y, Masuda O and Takano T: Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem. 60:488–489. 1996.PubMed/NCBI View Article : Google Scholar
121	Nakamura Y, Yamamoto N, Sakai K and Takano T: Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci. 78:1253–1257. 1995.PubMed/NCBI View Article : Google Scholar
122	Kim B, Park KY, Ji Y, Park S, Holzapfel W and Hyun CK: Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. Biochem Biophys Res Commun. 473:530–536. 2016.PubMed/NCBI View Article : Google Scholar
123	Derrien M and van Hylckama Vlieg JE: Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 23:354–366. 2015.PubMed/NCBI View Article : Google Scholar
124	Deng M, Zhang S, Wu S, Jiang Q, Teng W, Luo T, Ouyang Y, Liu J and Gu B: Lactiplantibacillus plantarum N4 ameliorates lipid metabolism and gut microbiota structure in high fat diet-fed rats. Front Microbiol. 7(1390293)2024.PubMed/NCBI View Article : Google Scholar
125	Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P and Gervais P: Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr. 54:175–189. 2014.PubMed/NCBI View Article : Google Scholar
126	Khalesi S, Sun J, Buys N and Jayasinghe R: Effect of probiotics on blood pressure: A systematic review and meta-analysis of randomized, controlled trials. Hypertension. 64:897–903. 2014.PubMed/NCBI View Article : Google Scholar
127	De Filippis F, Pellegrini N, Vannini L, Jeffery IB, Storia AL, Laghi L, Serrazanetti D, Cagno RD, Ferrocino I, Lazzi C, et al: High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 65:1812–1821. 2016.PubMed/NCBI View Article : Google Scholar
128	Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E and Trichopoulos D: Mediterranean diet pyramid: A cultural model for healthy eating. Am J Clin Nutr. 61:1402S–1406S. 1995.PubMed/NCBI View Article : Google Scholar
129	Sofi F, Abbate R, Gensini GF and Casini A: Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr. 92:1189–1196. 2010.PubMed/NCBI View Article : Google Scholar
130	Lopez-Garcia E, Rodriguez-Artalejo F, Li TY, Fung TT, Li S, Willett WC, Rimm EB and Hu FB: The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease. Am J Clin Nutr. 99:172–180. 2014.PubMed/NCBI View Article : Google Scholar
131	Cani PD, Delzenne NM, Amar J and Burcelin R: Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris). 56:305–309. 2008.PubMed/NCBI View Article : Google Scholar
132	Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, Li J, Liu X, Liu J, Guo Z, et al: Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome. 6(66)2018.PubMed/NCBI View Article : Google Scholar
133	Qi Y, Aranda JM, Rodriguez V, Raizada MK and Pepine CJ: Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension-A case report. Int J Cardiol. 201:157–158. 2015.PubMed/NCBI View Article : Google Scholar
134	Battson ML, Lee DM, Jarrell DK, Hou S, Ecton KE, Weir TL and Gentile CL: Suppression of gut dysbiosis reverses Western diet-induced vascular dysfunction. Am J Physiol Endocrinol Metab. 314:E468–E477. 2018.PubMed/NCBI View Article : Google Scholar